Will ranitidine ever make a comeback? (audio)

We take a closer look at why all licenses for ranitidine were suspended and ask whether it is likely to ever make a comeback.

Stomach acid-suppressing medicine ranitidine disappeared from pharmacy shelves two years ago, owing to fears of contamination with probable human carcinogen N-nitrosodimethylamine (NDMA).

In this episode of The PJ Pod, features editor Dawn Connelly finds out why.

She speaks with David Light, chief executive officer of Valisure, the online pharmacy that first identified the contamination in ranitidine, and Michael White, professor of pharmacy practice at the University of Connecticut, about the implications for other similar medicines.

Connelly also assesses recent evidence ranitidine could be about to make a comeback and discusses the problems of switching to alternative treatments with Mikin Patel, lead pharmacist in gastroenterology at Imperial College Healthcare NHS Trust, London, and Alisdair Jones, a primary care network pharmacist in Folkestone, Kent.

This episode was produced by Geoff Marsh and additional research was carried out by Emma Wilkinson.


Clinical advice on alternatives to ranitidine preparations for adults and children has been shared by the Department of Health and Social Care in the ranitidine supply disruption alert (see tables 1 and 2).

Want to hear more from The PJ Pod? Follow us on SpotifyGoogle PodcastsApple Podcasts or Soundcloud to download our latest podcasts.

Last updated
The Pharmaceutical Journal, PJ, September 2021, Vol 307, No 7953;307(7953)::DOI:10.1211/PJ.2021.1.107446

    Please leave a comment 

    You may also be interested in